Northwire Canada EditionFriday, October 16, 2026
Sign inSubscribe
Northwire
⌕
GOLD 4170.10 +1.5% SILVER 57.16 +2.3% COPPER 6.56 −1.5% OIL 97.97 +3.0% PALLADIUM 1136.00 +3.6% LUN 32.91 +0.6% DLP 0.290 −3.3% VCV 0.065 −13.3% GG 2.89 +1.4% NBLC 0.015 +0.0% SF 0.300 −4.8% ATY 0.215 +2.4% GHL 0.060 −7.7% STND 0.060 −7.7% B 0.550 −3.5% HBM 34.33 −0.5% NTR 98.77 −0.7% SGZ 0.035 +0.0% MKA 0.670 +0.0% LXM 0.175 −18.6% CLCH 1.08 −1.8% GOLD 4170.10 +1.5% SILVER 57.16 +2.3% COPPER 6.56 −1.5% OIL 97.97 +3.0% PALLADIUM 1136.00 +3.6% LUN 32.91 +0.6% DLP 0.290 −3.3% VCV 0.065 −13.3% GG 2.89 +1.4% NBLC 0.015 +0.0% SF 0.300 −4.8% ATY 0.215 +2.4% GHL 0.060 −7.7% STND 0.060 −7.7% B 0.550 −3.5% HBM 34.33 −0.5% NTR 98.77 −0.7% SGZ 0.035 +0.0% MKA 0.670 +0.0% LXM 0.175 −18.6% CLCH 1.08 −1.8%
Financings

MindBio Deploys New Technology Intox Collect(TM); Expands CNS Drug Detection Capabilities with Voice & Facial Recognition

MindBio Therapeutics Corp.

By The Northwire Desk — AI Analysis Apr 13, 2026 · 08:30 MBIO · 1.1 MindBio Therapeutics Corp.
Executive Summary
  • Date: April 13, 2026
  • Headline: MindBio Deploys New Technology Intox Collect(TM); Expands CNS Drug Detection Capabilities with Voice & Facial Recognition
  • Core Announcement: Completion of "Intox Collect" software enabling voice/facial recognition data collection for CNS substances. AI model trained on >50 million data points (targeting 150 million).
  • Hardware Roadmap: Edge AI hardware-software kiosk prototype nearing completion; field testing scheduled for late Q2 2026.
  • Financing Correction: Clarification of April 1, 2026 private placement. Cash finder's fees paid: $74,983.97. Finder Warrants issued: 124,973 at $0.80 exercise price (36-month term).
  • Capital Raise: Upsized private placement to $1.5 million total gross proceeds supports development and working capital.
Material Impact
  • Operational Progress: Confirms the company is executing on its February 2026 pivot from clinical drug trials (MB22001) to AI-based workplace safety diagnostics. However, this is a continuation of previously announced strategy rather than new information.
  • Financial Impact: The financing correction reveals significant cash fees ($75k) and warrant issuance associated with the capital raise. This increases the effective cost of capital without generating immediate revenue.
  • Revenue Reality: No commercial contracts or revenue are disclosed. The technology remains in prototype/testing phase (Q2 2026).
  • Risk Profile: The news does not address the fundamental solvency risk highlighted in December 2025 financials (negative equity of -$2M, high burn rate). It extends runway but increases dilution.
  • Market Expectation: The market was already aware of the financing (announced March/April) and the technology pivot (announced February). This release is administrative confirmation.
MBIO · Price
Company Overview
  • Overview: MindBio Therapeutics Corp. is a clinical-stage biotechnology company that has pivoted to AI-driven digital health diagnostics following negative Phase 2B results for its lead drug candidate.
  • Flagship Project (Legacy): MB22001 (Microdosed LSD for Major Depressive Disorder). Phase 2B trial completed November 2025 showed no statistical superiority over placebo.
  • Flagship Project (Current): Intox Collect™ / Edge AI Platform. Voice and facial recognition software to detect intoxication in workplace settings (mining, aviation). Currently in prototype/testing phase with no commercial revenue.
Read the original news release →

More from MindBio Therapeutics Corp.

Jun 09, 2026 · 07:00

From failed psychedelics to unproven AI kiosks: MindBio bets its survival on voice analytics, but cash burn and dilution loom.

Production / Operations Jun 04, 2026 · 11:12

MindBio’s Voice AI Pivot Buys Time, But Cash Runway and Dilution Risk Keep the Stock in the Red Zone

Other May 15, 2026 · 08:30

MindBio's AI Pivot Masks Failed Drug Trial and Dilution Risk

Other May 14, 2026 · 08:30

MindBio Pivots from Failed Psychedelic Trial to AI Voice Detection Amidst Dilution Concerns

Other May 13, 2026 · 08:30

MindBio Pivots to AI Voice Tech After Clinical Setback; Dilution Risks Loom

Other May 11, 2026 · 08:45

MindBio Pivots from Clinical Failure to AI Voice Analytics, But Dilution Risks Loom

Other